MedTrace Logo

Trial Evaluating Postop Pain and Muscle Strength Among Regional Anesthesia Techniques for Ambulatory ACL Reconstruction

NCT02584452 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2019-12-11

Study results available
· View outcomes & findings →

Summary

Despite the apparent multifaceted benefit in differentiating blockade sites and duration of nerve blockade, the efficacy of continuous adductor canal blockade utilized specifically in ACL reconstruction has not been extensively studied. This study will test the hypothesis that the use of the adductor canal continuous nerve catheter will result in lower subjective pain scores on postoperative day 2 and improved quadriceps strength on postoperative day 1.

Conditions

  • Rupture of Anterior Cruciate Ligament
  • Tear of Anterior Cruciate Ligament

Interventions

DRUG

Mepivacaine

20cc of 2% mepivacaine \<20 minutes prior to in room time.

PROCEDURE

adductor canal continuous nerve catheter

Placement of ultrasound guided adductor canal continuous nerve catheter

DRUG

Normal Saline as bolus followed by bupivacaine

normal saline as bolus for placement, followed by initiation of 1/8% bupivacaine infusion through adductor canal catheter at 8cc/h

PROCEDURE

adductor canal nerve block

ultrasound guided adductor canal nerve block

DRUG

ropivacaine and dexamethasone

10cc of 0.5% ropivacaine + 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve

DRUG

Propofol

Anesthesia induction will include a propofol bolus.

DRUG

Fentanyl

Intraoperative opioid should be limited to no more than 150mcg of fentanyl.

Sponsors & Collaborators

  • Vanderbilt University Medical Center

    lead OTHER

Principal Investigators

  • Christopher Sobey, MD · Vanderbilt University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-03
Primary Completion
2018-03-01
Completion
2018-04-10

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02584452 on ClinicalTrials.gov